{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:45:33Z","timestamp":1791215133944,"version":"4.1.0"},"reference-count":67,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,3,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>We previously found that the risk of invasive breast cancer varied according to the progestagen component of combined postmenopausal hormone therapy (CHT): progesterone, dydrogesterone, or other progestagens. We conducted the present study to assess how these CHTs were associated with histology- and hormone receptor-defined breast cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>We used data from the French E3N cohort study, with 80,391 postmenopausal women followed for a mean duration of 8.1 years; 2,265 histologically confirmed invasive breast cancers were identified through biennial self-administered questionnaires completed from 1990 to 2002. The relative risks (RRs) were estimated using Cox proportional hazards models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with postmenopausal hormone therapy (HT) never-use, ever-use of estrogen+progesterone was not significantly associated with the risk of any breast cancer subtype, but increasing duration of estrogen+progesterone was associated with increasing risks of lobular (P = .06) and estrogen receptor\u2013positive\/progesterone receptor\u2013negative (ER+\/PR\u2212; P = .02). Estrogen+dydrogesterone was associated with a significant increase in risk of lobular carcinoma (RR, 1.7; 95% CI, 1.1 to 2.6). Estrogen+other progestagens was associated with significant increases in risk of ductal and lobular carcinomas (RR, 1.6; 95% CI, 1.3 to 1.8; and 2.0; 95% CI, 1.5 to 2.7, respectively), of ER+\/PR+ and ER+\/PR\u2212 carcinomas (RR, 1.8; 95% CI, 1.5 to 2.1; and 2.6; 95% CI, 1.9 to 3.5, respectively), but not of ER\u2212\/PR+ or ER\u2212\/PR\u2212 carcinomas (RR, 1.0; 95% CI, 0.5 to 2.1; and 1.4; 95% CI, 0.9 to 2.0, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The increase in risk of breast cancer observed with the use of CHTs other than estrogen+progesterone and estrogen+dydrogesterone seems to apply preferentially to ER+ carcinomas, especially those ER+\/PR\u2212, and to affect both ductal and lobular carcinomas.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2007.13.4338","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T23:24:26Z","timestamp":1204845866000},"page":"1260-1268","source":"Crossref","is-referenced-by-count":157,"title":["Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor\u2013Defined Invasive Breast Cancer"],"prefix":"10.1200","volume":"26","author":[{"given":"Agn\u00e8s","family":"Fournier","sequence":"first","affiliation":[{"name":"From the Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Villejuif, France; Institut Gustave Roussy, Villejuif; EA4045, Universite Paris-Sud, Paris, France; and Istituto Nazionale Tumori, Department of Preventive and Predictive Medicine, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Fabre","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Villejuif, France; Institut Gustave Roussy, Villejuif; EA4045, Universite Paris-Sud, Paris, France; and Istituto Nazionale Tumori, Department of Preventive and Predictive Medicine, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Mesrine","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Villejuif, France; Institut Gustave Roussy, Villejuif; EA4045, Universite Paris-Sud, Paris, France; and Istituto Nazionale Tumori, Department of Preventive and Predictive Medicine, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Boutron-Ruault","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Villejuif, France; Institut Gustave Roussy, Villejuif; EA4045, Universite Paris-Sud, Paris, France; and Istituto Nazionale Tumori, Department of Preventive and Predictive Medicine, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Berrino","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Villejuif, France; Institut Gustave Roussy, Villejuif; EA4045, Universite Paris-Sud, Paris, France; and Istituto Nazionale Tumori, Department of Preventive and Predictive Medicine, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Clavel-Chapelon","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Villejuif, France; Institut Gustave Roussy, Villejuif; EA4045, Universite Paris-Sud, Paris, France; and Istituto Nazionale Tumori, Department of Preventive and Predictive Medicine, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70273-4"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Anderson WF, Chu KC, Chang S, et al: Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 13:1128,2004-1135,","DOI":"10.1158\/1055-9965.1128.13.7"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0881"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Ma H, Bernstein L, Pike MC, et al: Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: A meta-analysis of epidemiological studies. Breast Cancer Res 8:R43,2006,","DOI":"10.1186\/bcr1525"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602617"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9523-x"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000601)88:11<2561::AID-CNCR19>3.0.CO;2-X"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.11.1421"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11309"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11032"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9554-3"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.699"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.6.734"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10984"},{"key":"R16","unstructured":"Newcomb PA, Titus-Ernstoff L, Egan KM, et al: Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:593,2002-600,"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023634907723"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3254"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3243"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21481"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603207"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Rosenberg LU, Magnusson C, Lindstrom E, et al: Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: A case-control study. Breast Cancer Res 8:R11,2006,","DOI":"10.1186\/bcr1378"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70911-1"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22542"},{"key":"R25","unstructured":"Hildreth NG, Kelsey JL, Eisenfeld AJ, et al: Differences in breast cancer risk factors according to the estrogen receptor level of the tumor. J Natl Cancer Inst 70:1027,1983-1031,"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a114519"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.24"},{"key":"R28","unstructured":"Potter JD, Cerhan JR, Sellers TA, et al: Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: How many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 4:319,1995-326,"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010265"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.151"},{"key":"R31","unstructured":"Cotterchio M, Kreiger N, Theis B, et al: Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev 12:1053,2003-1060,"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601996"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20499"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20250"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.14.1647"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0489"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh112"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1079\/PHN2002394"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Weiss NS, Rossing MA: Healthy screened bias in epidemiologic studies of cancer incidence. Epidemiology 7:319,1996-322,","DOI":"10.1093\/oxfordjournals.aje.a008745"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.2307\/2347158"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602787"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010220"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009515"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2005.02.014"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(98)00028-4"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2003.08.003"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(03)00138-7"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1981.168"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198606000-00003"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)57482-2"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(98)00042-9"},{"key":"R52","doi-asserted-by":"crossref","unstructured":"Hofseth LJ, Raafat AM, Osuch JR, et al: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84:4559,1999-4565,","DOI":"10.1210\/jc.84.12.4559"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(96)70379-4"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-006-9276-y"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.1186\/bcr452"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr070105"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2006.06.002"},{"key":"R58","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11836"},{"key":"R59","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(94)90170-8"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.1210\/mend-2-1-62"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1210\/me.2002-0318"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.3115"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1007\/BF02524346"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2005.02.005"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.47.31308"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-7726-6"},{"key":"R67","unstructured":"Murphy LJ, Sutherland RL, Stead B, et al: Progestin regulation of epidermal growth factor receptor in human mammary carcinoma cells. Cancer Res 46:728,1986-734,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.13.4338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T21:45:45Z","timestamp":1684273545000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.13.4338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,10]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,3,10]]}},"alternative-id":["10.1200\/JCO.2007.13.4338"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.13.4338","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,10]]}}}